Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Peter MacCallum Cancer Centre · St Vincent's Hospital Melbourne · +33 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
269
total citations
- FWCI
- 36.61
- Percentile
- 100%
- References
- 30
Citations per year
Authors
31- CSConstantine S. TamCorresponding
Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, The Royal Melbourne Hospital, The University of Melbourne
- JRJennifer R. Brown
Dana-Farber Cancer Institute
- BSBrad S. Kahl
Washington University in St. Louis
- PGPaolo Ghia
IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University
- KGKrzysztof Giannopoulos
Medical University of Lublin
Topics & keywords
Topics
Keywords
- Bendamustine
- Medicine
- Rituximab
- Chronic lymphocytic leukemia
- Internal medicine
- Population
- Progression-free survival
- Clinical endpoint
No related works found for this paper.